Home Newsfeeds SVB Leerink Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $3

SVB Leerink Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $3

SVB Leerink analyst Andrew Berens maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from $4 to $3.

byBenzinga Newsdesk

August 11, 2022

1 minute read

SVB Leerink analyst Andrew Berens maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from $4 to $3.

Balaji Srinivasan Ends Bitcoin Bet 97% Below Target Price: Not In ‘Habit Of Publicly Burning A Million Bucks’

By Mehab Qureshi

May 3, 3:54 AM

Balaji Srinivasan, the former CTO at Coinbase (NASDAQ:COIN), has closed out his $1 million bet on Bitcoin (CRYPTO: BTC), conceding defeat as the apex cryptocurrency has declined 97%

BTC

Energy Transfer Q4 EPS $0.34 Misses $0.39 Estimate, Sales $20.50B Miss $23.81B Estimate

By Benzinga Newsdesk

February 15, 5:39 PM

Energy Transfer (NYSE:ET) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.39 by 12.82 percent. This is a 17.24 percent increase over earnings of $0.29 per share from the

All Eyes Are On Friday’s Jobs Report: Data Is Critical For Fed’s Next Move In Brawl With Sticky Inflation

By Adam Eckert

March 9, 3:42 PM

Thursday's jobs data suggests the labor market might finally be starting to roll over, but attention is shifting to Friday's non-farm payrolls report, which Fed Chair Jerome Powell flagged this week as key to understanding the

SPY

Bunge Q2: Sales Plunge 16%, Beats On EPS, Boosts FY23 EPS Outlook & More

By Shivani Kumaresan

August 2, 9:03 AM

Bunge Ltd (NYSE: BG) reported a

SVB Leerink Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $3

Related Posts

Balaji Srinivasan Ends Bitcoin Bet 97% Below Target Price: Not In ‘Habit Of Publicly Burning A Million Bucks’

Energy Transfer Q4 EPS $0.34 Misses $0.39 Estimate, Sales $20.50B Miss $23.81B Estimate

All Eyes Are On Friday’s Jobs Report: Data Is Critical For Fed’s Next Move In Brawl With Sticky Inflation

Bunge Q2: Sales Plunge 16%, Beats On EPS, Boosts FY23 EPS Outlook & More